



COPY OF PAPERS  
ORIGINALLY FILED

PATENT

Practitioner's Docket No. 3115.00017

1646  
#6  
JP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUL 22 2002

TECH CENTER 1600/2900

In re application of: Hadden

Serial Number: 10/015,123

Group Art Unit:

Filed: 10/26/01

Examiner:

For: VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR 1.97(e)(1)

Box DD  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Provided herewith are copies of patents and publications as listed in the attached PTO-1449 (supplemental).

Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application mailed not more than three months prior to the filing of the statement. 37 CFR 1.97(e)(1).

While the statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such. The filing of this statement does not mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.

Please charge our Deposit Account No. 11-1449 for any additional fees or credit our account for any overpayment. A duplicate of this transmittal is attached.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington

D.C. 20231, on

9/6/02  
(Date of Deposit)

*Angel Webb*  
Signature

7/9/02  
(Date of Signature)

Respectfully submitted,

KOHN & ASSOCIATES

*Kenneth I. Kohn*

Kenneth I. Kohn  
Registration No. 30,955  
30500 Northwestern Hwy.  
Suite 410  
Farmington Hills, MI 48334  
(248) 539-5050

Date: July 9, 2002

MANUAL OF PATENT EXAMINING PROCEDURE  
PTO/SB/08 (2-92)

Sheet 1 of 1

Form PTO-1449				Docket Number (Optional) 3115.00017		Application Number 10/015,123	
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				Applicant John Hadden		Filing Date 10/26/01	
				Group Art Unit Unknown			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS							
	DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)							
	Barrera J, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW. "Clinical and pathological responses induced by a neoadjuvant treatment with a cytokine mixture (IRX-2) in oral cavity squamous cell carcinoma of head and neck." International Journal on Immunorehabilitation, Vol. 2, No. 3, pp. 29-32, 2000.						
	Barrera J, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW. "Clinical and pathological bio-responses induced with a cytokine mixture (IRX-2) in patients with oral cavity squamous cell carcinoma." Clinical and Applied Immunology Reviews, 1:181-185, 2001.						
	Cortesina G, DeStefani A, Galcazzi E, Cavallo GP, Jemma C, Giovarelli M, Vai S, Forni G. "Interleukin-2 Injected Adjuvant Tumor-Draining Lymph Nodes In Head and Neck Cancer." Head & Neck, pp.125-131, March/April 1991.						
	Goldstein, A. "Vaccine Adjuvant In Immunocompromised Patients." pp. 47-50.						
	Hadden JW, Endicott J, Baeky P, Skipper P, Hadden EM. "Interleukins and contrasuppression induce immune regression of head and neck cancer", Arch otolaryngol Head Neck Surg. 120:395-403, 1994.						
	Musiani P, DeCampora E, Valitutti S, Castellino F, Calearo C, Cortesina G, Giovarelli M, Jemma C, DeStefani A, Forni G. "Effect of Low Doses of Interleukin-2 Injected Perilymphatically and Peritumorally in Patients with Advanced Primary Head and Neck Squamous Cell Carcinoma." Journal of Biological Response Modifiers, 8:571-578, Raven Press, Ltd., New York, 1989.						
	Webb SR, Cooper MD. "T Cells Can Bind Antigen via Cytophilic IgM Antibody Made by B Cells." The Journal of Immunology, Vol. 111, No. 1, pp. 275-277, July 1973.						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							